Dear customers,
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal https://eifu.r-biopharm.com.
Respiratory infections
Coronavirus test kit receives CE label
In February 2020, R-Biopharm was one of the first diagnostics companies worldwide to launch a test kit for the novel coronavirus SARS-CoV-2. Now, the test has received the CE label and is thus [...]
Legionella and mycoplasma pneumoniae: New RIDA®GENE products for detection of atypical CAP bacteria
Community-acquired pneumonia (CAP) is the most common fatal infectious disease in western countries. Bacteria are the most common pathogens causing CAP, where one differentiates between typical [...]
Back to school in the time of the coronavirus – what can we expect?
The COVID-19 infection figures continue to rise and with them the fear: How long can regular school operations be maintained? Experts warn of renewed school closings and recommend specific measures.
Safe into the upcoming influenza season with RIDA®GENE real-time PCR assays
The RIDA®GENE real-time PCR assays (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) successfully detected the suggested vaccination strains for influenca of the 2015/2016 season.
Virology
RIDA®GENE Enterovirus: New real-time RT-PCR assay
RIDA®GENE Enterovirus – the new real-time RT-PCR assay for the detection of the major human enteroviruses